Title
Investor Protection and Corporate Governance: Firmlevel Evidence Across Latin America (Latin American Development Forum),New
Sold by Ergodebooks, an authorized reseller.
Returns accepted within 30 days | support@ergodebooks.com
Shipping Information
- Free Standard Shipping — United States only
- Processing Time: 1–3 business days
- Estimated Delivery: 3–5 business days after dispatch
- Double-boxed, fully insured & discreetly packaged
- Tracking number sent via email once dispatched
- Orders over $250 require signature upon delivery. Taxes calculated at checkout.
Returns & Refund
Returns accepted within 30 days of delivery.
Damaged or Defective Item
Free return shipping + replacement or full refund
Wrong Item Received
Free return shipping + replacement or full refund
Change of Mind
Return shipping at customer's expense · 25% restocking fee applies
Payment Option
Latin America has been surprisingly spared from a generalized wave of corporate governance scandals. One possible explanation is that the regions level of investor protection is adequate. The evidence from the papers in this book says otherwise. The still relatively low level of protection and transparency has created an environment where problems cannot be easily detected or are not worth pursuing. These circumstances have started to push firms thirsty for capital to unilaterally opt for better corporate governance and alleviate this disadvantage. The papers in this book constitute the largest firmlevel corporate governance analysis undertaken across Latin American countries. The new datasets in the book allow the researchers to conclude that companies with better selfimposed firmlevel governance practices or with listing in U.S. markets are given higher valuations and can raise capital at a lower cost. Although these results are encouraging, they point to a rocky path for the future growth of local Latin American capital markets.
⚠️ WARNING (California Proposition 65):
This product may contain chemicals known to the State of California to cause cancer, birth defects, or other reproductive harm.
For more information, please visit www.P65Warnings.ca.gov.